KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Amortizatization of Intangibles (2016 - 2026)

Biocryst Pharmaceuticals filings provide 11 years of Amortizatization of Intangibles readings, the most recent being -$1.1 million for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles rose 60.47% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.3 million, a 62.25% increase, with the full-year FY2025 number at -$4.3 million, up 62.25% from a year prior.
  • Amortizatization of Intangibles hit -$1.1 million in Q4 2025 for Biocryst Pharmaceuticals, down from -$707000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $30000.0 in Q1 2022 to a low of -$3.5 million in Q2 2024.
  • Median Amortizatization of Intangibles over the past 5 years was -$1.1 million (2025), compared with a mean of -$1.4 million.
  • Biggest five-year swings in Amortizatization of Intangibles: soared 250.0% in 2021 and later tumbled 73100.0% in 2022.
  • Biocryst Pharmaceuticals' Amortizatization of Intangibles stood at -$37000.0 in 2021, then crashed by 2491.89% to -$959000.0 in 2022, then tumbled by 259.65% to -$3.4 million in 2023, then increased by 19.98% to -$2.8 million in 2024, then skyrocketed by 60.47% to -$1.1 million in 2025.
  • The last three reported values for Amortizatization of Intangibles were -$1.1 million (Q4 2025), -$707000.0 (Q3 2025), and -$1.2 million (Q2 2025) per Business Quant data.